Abstract
Background Alcohol use disorders (AUDs) are highly prevalent among persons living with HIV (PLH) within the criminal justice system (CJS). Extended-release naltrexone (XR-NTX) has not been previously evaluated among CJS-involved PLH with AUDs. Methods A randomized, double-blind, placebo-controlled trial was conducted among 100 HIV+ prisoners with AUDs. Participants were randomized 2:1 to receive 6 monthly injections of XR-NTX or placebo starting one week prior to release. Using multiple imputation strategies for data missing completely at random, data were analyzed for the 6-month post-incarceration period. Main outcomes included: time to first heavy drinking day; number of standardized drinks/drinking day; percent of heavy drinking days; pre- to post-incarceration change in average drinks/day; total number of drinking days; and a composite alcohol improvement score comprised of all 5 parameters. Results There was no statistically significant difference overall between treatment arms for time-to-heavy-drinking day. However, participants aged 20–29 years who received XR-NTX had a longer time to first heavy drinking day compared to the placebo group (24.1 vs. 9.5 days; p < 0.001). There were no statistically significant differences between groups for other individual drinking outcomes. A sub-analysis, however, found participants who received ≥4 XR-NTX were more likely (p < 0.005) to have improved composite alcohol scores than the placebo group. Post-hoc power analysis revealed that despite the study being powered for HIV outcomes, sufficient power (0.94) was available to distinguish the observed differences. Conclusions Among CJS-involved PLH with AUDs transitioning to the community, XR-NTX lengthens the time to heavy drinking day for younger persons; reduces alcohol consumption when using a composite alcohol consumption score; and is not associated with any serious adverse events.
Author supplied keywords
Cite
CITATION STYLE
Springer, S. A., Di Paola, A., Azar, M. M., Barbour, R., Krishnan, A., & Altice, F. L. (2017). Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug and Alcohol Dependence, 174, 158–170. https://doi.org/10.1016/j.drugalcdep.2017.01.026
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.